Sacituzumab govitecan - Immunomedics

Drug Profile

Sacituzumab govitecan - Immunomedics

Alternative Names: hRS7-SN38 antibody drug conjugate; IMMU-132; Isactuzumab govitecan; TROP-2-SN-38

Latest Information Update: 02 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IBC Pharmaceuticals; Immunomedics
  • Developer Immunomedics
  • Class Antineoplastics; Camptothecins; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer; Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Breast cancer
  • Phase II Solid tumours
  • No development reported Pancreatic cancer; Small cell lung cancer

Most Recent Events

  • 30 Jul 2018 Immunomedics signs a collaboration agreement with Yale University to evaluate sacituzumab govitecan in two phase II trials in Endometrial and Cervical Cancers and preclinical studies in Gynaecological cancer
  • 30 Jul 2018 Immunomedics signs a research collaboration agreement with Fred Hutchinson Cancer Research Center for evaluation of sacituzumab govitecan in treatment of Prostate cancer (Monotherapy, Combination therapy)
  • 30 Jul 2018 Immunomedics signs a research collaboration agreement with the Memorial Sloan Kettering Cancer Center for evaluation of sacituzumab govitecan in Head and neck cancer (Monotherapy, Combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top